Dr. Foy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9200 W Wisconsin Ave
# Division
Milwaukee, WI 53226Phone+1 414-805-6800Fax+1 414-805-6808
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 2007 - 2010- University of MinnesotaResidency, Internal Medicine, 2004 - 2007
Loyola University Chicago Stritch School of MedicineClass of 2004
Certifications & Licensure
WI State Medical License 2010 - 2025
MN State Medical License 2008 - 2010
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- A Phase II Trial of Regadenoson in Sickle Cell Anemia Start of enrollment: 2013 Jul 01
Publications & Presentations
PubMed
- 21 citationsEffect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding.Narendranath Epperla, Jonathan Kapke, Matthew S. Karafin, Kenneth D. Friedman, Patrick Foy
American Journal of Hematology. 2016-06-01 - 5 citationsDifficult to swallow: warm autoimmune hemolytic anemia in a Jehovah's Witness treated with hemoglobin concentrate complicated by achalasiaNarendranath Epperla, Christopher Strouse, Amanda M. VanSandt, Patrick Foy
Transfusion. 2016-07-01 - 5 citationsRe-treatment versus extended treatment strategy of systemic bevacizumab in hereditary hemorrhagic telangiectasia: which is better?Narendranath Epperla, Ariel Kleman, Matthew S. Karafin, Patrick Foy
Annals of Hematology. 2018-04-14
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
